Eutropin ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
78	Hypopituitarism	2
193	Prader-Willi syndrome	1

78. Hypopituitarism

---

Clinical trials : 494 /  Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03015909 (ClinicalTrials.gov)	August 11, 2016	10/11/2016	Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.	A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device	Short Stature, Idiopathic;Infant, Small for Gestational Age;Growth Hormone Deficiency;Chronic Renal Failure;Turner Syndrome	Drug: Somatropin	LG Life Sciences	NULL	Completed	4 Years	15 Years	All	116	Phase 4	Korea, Republic of
2	NCT02693522 (ClinicalTrials.gov)	October 2003	19/1/2016	Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency	Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency	Growth Hormone Deficiency	Drug: somatropin;Drug: Eutropin	Daewoong Pharmaceutical Co. LTD.	NULL	Completed	18 Years	N/A	Both	52	Phase 3	Korea, Republic of

193. Prader-Willi syndrome

---

Clinical trials : 111 /  Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02204163 (ClinicalTrials.gov)	June 2014	25/7/2014	Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome	A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome	Prader-Willi Syndrome	Drug: Eutropin;Drug: Genotropin	LG Life Sciences	NULL	Completed	N/A	N/A	All	34	Phase 3	Korea, Republic of